Perioperative rifaximin is not associated with enhanced functional and volumetric recovery after major liver resection

The objective of this randomized controlled trial (RCT) was to assess the impact of rifaximin on the course of liver function, liver regeneration and volumetric recovery in patients undergoing major hepatectomy. The ARROW trial was an investigator initiated, single-center, open-label, phase 3 RCT wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bednarsch, Jan, Czigany, Zoltan, Loosen, Sven H., Heij, Lara, Ruckgaber, Lorenz, Maes, Henning, Krause, Jan-Pit, Reen, Matthias, Toteva, Beata, Vosdellen, Theresa, Bruners, Philipp, Lang, Sven Arke, Ulmer, Tom Florian, Roderburg, Christoph, Luedde, Tom, Neumann, Ulf Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429542/
https://www.ncbi.nlm.nih.gov/pubmed/34504196
http://dx.doi.org/10.1038/s41598-021-97442-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429542/
https://www.ncbi.nlm.nih.gov/pubmed/34504196
http://dx.doi.org/10.1038/s41598-021-97442-w

Ejemplares similares